在日本的非小细胞肺癌患者中检测药物可用突变的回顾性数据库研究
Yuya Yokochi1, Moemi Miura2, Masayuki Hamakawa2
1Medical Affairs Division, Novartis Pharma K.K, 23-1, Toranomon 1-chome, Minato-ku, Tokyo, 105-6333, Japan. yuya.yokochi@novartis.com.
Scientific reports
|May 21, 2025
概括
几乎一半的非小细胞肺癌 (NSCLC) 患者有可通过癌症基因组 (CGP) 测试检测到的可操作突变. 早期CGP测试对于指导NSCLC患者的向治疗至关重要.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 医学诊断 医学诊断 医学诊断
背景情况:
- 非小细胞肺癌 (NSCLC) 是日本的主要肺癌类型.
- 识别可向突变对于NSCLC个性化全身疗法至关重要.
- 标准治疗通常在检测可操作突变之前进行.
研究的目的:
- 确定NSCLC患者可操作突变的患病率和特征.
- 通过CGP测试检测可操作突变后,分析NSCLC患者接受的治疗.
- 强调及时进行多基因测试对NSCLC治疗选择的重要性.
主要方法:
- 从国家数据库中对成年NSCLC病例的回顾性分析.
- 纳入标准:在CGP测试之前没有先前确诊的可药性突变的患者.
- 用描述性统计数据分析了1425个案例.
主要成果:
- 44.6%的NSCLC患者 (635/1,425) 具有可检测的可用药物的突变.
- EGFR和NTRK是最常见的突变;肺腺癌和状细胞癌是常见的亚型.
- 从初级治疗到突变检测的中位时间为701天.
- 23.0%的患者接受了CGP测试后的分子向药物.
结论:
- 显著比例的NSCLC患者携带有针对性的突变.
- 检测这些突变存在延迟,影响及时治疗.
- 减少前期多基因测试的障碍对于最佳的NSCLC患者护理至关重要.
更多相关视频
11:20Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
10.8K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
996
相关概念视频
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
